Keytruda and Merck article about problems with lung cancer trial., page-2

As cavatak makes their drug more effective and safer, I see it as a good thing for vla. Merck was starting to win the battle against BMS. Now there's still a fight.

Merck and BMS are in a battle, and cavatak seems to make both better and safer.

Surely it can't be long until one jumps on vla. It's makes sense to not only improve your product but to stop the opposition from improving theirs.

Perhaps the upcoming results will be the catalyst.

cheers